Notice of Proposals To Engage in or To Acquire Companies Engaged in Permissible Nonbanking Activities, 62786 [2023-19773]
Download as PDF
ddrumheller on DSK120RN23PROD with NOTICES1
62786
Federal Register / Vol. 88, No. 176 / Wednesday, September 13, 2023 / Notices
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
Board of Governors of the Federal Reserve
System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023–19770 Filed 9–12–23; 8:45 am]
[FR Doc. 2023–19773 Filed 9–12–23; 8:45 am]
BILLING CODE P
BILLING CODE P
FEDERAL RESERVE SYSTEM
FEDERAL TRADE COMMISSION
Notice of Proposals To Engage in or
To Acquire Companies Engaged in
Permissible Nonbanking Activities
[File No. 231 0037]
The companies listed in this notice
have given notice under section 4 of the
Bank Holding Company Act (12 U.S.C.
1843) (BHC Act) and Regulation Y, (12
CFR part 225) to engage de novo, or to
acquire or control voting securities or
assets of a company, including the
companies listed below, that engages
either directly or through a subsidiary or
other company, in a nonbanking activity
that is listed in § 225.28 of Regulation Y
(12 CFR 225.28) or that the Board has
determined by Order to be closely
related to banking and permissible for
bank holding companies. Unless
otherwise noted, these activities will be
conducted throughout the United States.
The public portions of the
applications listed below, as well as
other related filings required by the
Board, if any, are available for
immediate inspection at the Federal
Reserve Bank(s) indicated below and at
the offices of the Board of Governors.
This information may also be obtained
on an expedited basis, upon request, by
contacting the appropriate Federal
Reserve Bank and from the Board’s
Freedom of Information Office at
https://www.federalreserve.gov/foia/
request.htm. Interested persons may
express their views in writing on the
question whether the proposal complies
with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments
regarding the applications must be
received at the Reserve Bank indicated
or the offices of the Board of Governors,
Ann E. Misback, Secretary of the Board,
20th Street and Constitution Avenue
NW, Washington, DC 20551–0001, not
later than September 28, 2023.
A. Federal Reserve Bank of Boston
(Prabal Chakrabarti, Senior Vice
President) 600 Atlantic Avenue, Boston,
Massachusetts 02210–2204. Comments
can also be sent electronically to
BOS.SRC.Applications.Comments@
bos.frb.org:
1. Santander Holdings USA, Inc.,
Boston, Massachusetts; to engage in
community development activities
pursuant to section 225.28(b)(12) of the
Board’s Regulation Y.
VerDate Sep<11>2014
17:37 Sep 12, 2023
Jkt 259001
Amgen Inc. and Horizon Therapeutics
plc; Analysis of Agreement Containing
Consent Order To Aid Public Comment
Federal Trade Commission.
Proposed consent agreement;
request for comment.
AGENCY:
ACTION:
The consent agreement in this
matter settles alleged violations of
federal law prohibiting unfair methods
of competition. The attached Analysis of
Proposed Consent Order to Aid Public
Comment describes both the allegations
in the complaint and the terms of the
consent order—embodied in the consent
agreement—that would settle these
allegations.
SUMMARY:
Comments must be received on
or before October 13, 2023.
ADDRESSES: Interested parties may file
comments online or on paper by
following the instructions in the
Request for Comment part of the
SUPPLEMENTARY INFORMATION section
below. Please write: ‘‘Amgen Inc. and
Horizon Therapeutics plc; File No. 231
0037’’ on your comment and file your
comment online at https://
www.regulations.gov by following the
instructions on the web-based form. If
you prefer to file your comment on
paper, please mail your comment to the
following address: Federal Trade
Commission, Office of the Secretary,
600 Pennsylvania Avenue NW, Suite
CC–5610 (Annex T), Washington, DC
20580.
DATES:
FOR FURTHER INFORMATION CONTACT:
Stephen Mohr (202–326–2850), Bureau
of Competition, Federal Trade
Commission, 400 7th Street SW,
Washington, DC 20024.
SUPPLEMENTARY INFORMATION: Pursuant
to section 6(f) of the Federal Trade
Commission Act, 15 U.S.C. 46(f), and
FTC Rule § 2.34, 16 CFR 2.34, notice is
hereby given that the above-captioned
consent agreement containing a consent
order to cease and desist, having been
filed with and accepted, subject to final
approval, by the Commission, has been
placed on the public record for a period
of 30 days. The following Analysis of
Agreement Containing Consent Orders
to Aid Public Comment describes the
PO 00000
Frm 00017
Fmt 4703
Sfmt 4703
terms of the consent agreement and the
allegations in the complaint. An
electronic copy of the full text of the
consent agreement package can be
obtained from the FTC website at this
web address: https://www.ftc.gov/newsevents/commission-actions.
You can file a comment online or on
paper. For the Commission to consider
your comment, we must receive it on or
before October 13, 2023. Write ‘‘Amgen
Inc. and Horizon Therapeutics plc; File
No. 231 0037’’ on your comment. Your
comment—including your name and
your state—will be placed on the public
record of this proceeding, including, to
the extent practicable, on the https://
www.regulations.gov website.
Because of the agency’s heightened
security screening, postal mail
addressed to the Commission will be
delayed. We strongly encourage you to
submit your comments online through
the https://www.regulations.gov
website. If you prefer to file your
comment on paper, write ‘‘Amgen Inc.
and Horizon Therapeutics plc; File No.
231 0037’’ on your comment and on the
envelope, and mail your comment to the
following address: Federal Trade
Commission, Office of the Secretary,
600 Pennsylvania Avenue NW, Suite
CC–5610 (Annex T), Washington, DC
20580.
Because your comment will be placed
on the publicly accessible website at
https://www.regulations.gov, you are
solely responsible for making sure your
comment does not include any sensitive
or confidential information. In
particular, your comment should not
include sensitive personal information,
such as your or anyone else’s Social
Security number; date of birth; driver’s
license number or other state
identification number, or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. You are also solely
responsible for making sure your
comment does not include sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, your comment should not
include any ‘‘trade secret or any
commercial or financial information
which . . . is privileged or
confidential’’—as provided by section
6(f) of the FTC Act, 15 U.S.C. 46(f), and
FTC Rule § 4.10(a)(2), 16 CFR
4.10(a)(2)—including competitively
sensitive information such as costs,
sales statistics, inventories, formulas,
patterns, devices, manufacturing
processes, or customer names.
Comments containing material for
which confidential treatment is
requested must be filed in paper form,
E:\FR\FM\13SEN1.SGM
13SEN1
Agencies
[Federal Register Volume 88, Number 176 (Wednesday, September 13, 2023)]
[Notices]
[Page 62786]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-19773]
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Notice of Proposals To Engage in or To Acquire Companies Engaged
in Permissible Nonbanking Activities
The companies listed in this notice have given notice under section
4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and
Regulation Y, (12 CFR part 225) to engage de novo, or to acquire or
control voting securities or assets of a company, including the
companies listed below, that engages either directly or through a
subsidiary or other company, in a nonbanking activity that is listed in
Sec. 225.28 of Regulation Y (12 CFR 225.28) or that the Board has
determined by Order to be closely related to banking and permissible
for bank holding companies. Unless otherwise noted, these activities
will be conducted throughout the United States.
The public portions of the applications listed below, as well as
other related filings required by the Board, if any, are available for
immediate inspection at the Federal Reserve Bank(s) indicated below and
at the offices of the Board of Governors. This information may also be
obtained on an expedited basis, upon request, by contacting the
appropriate Federal Reserve Bank and from the Board's Freedom of
Information Office at https://www.federalreserve.gov/foia/request.htm.
Interested persons may express their views in writing on the question
whether the proposal complies with the standards of section 4 of the
BHC Act.
Unless otherwise noted, comments regarding the applications must be
received at the Reserve Bank indicated or the offices of the Board of
Governors, Ann E. Misback, Secretary of the Board, 20th Street and
Constitution Avenue NW, Washington, DC 20551-0001, not later than
September 28, 2023.
A. Federal Reserve Bank of Boston (Prabal Chakrabarti, Senior Vice
President) 600 Atlantic Avenue, Boston, Massachusetts 02210-2204.
Comments can also be sent electronically to
[email protected]:
1. Santander Holdings USA, Inc., Boston, Massachusetts; to engage
in community development activities pursuant to section 225.28(b)(12)
of the Board's Regulation Y.
Board of Governors of the Federal Reserve System.
Michele Taylor Fennell,
Deputy Associate Secretary of the Board.
[FR Doc. 2023-19773 Filed 9-12-23; 8:45 am]
BILLING CODE P